iparomlimab + tuvonralimab + gemcitabine + oxaliplatin + lenvatinib

This combination therapy is an investigational regimen being evaluated as conversion therapy for patients with initially potentially resectable intrahepatic cholangiocarcinoma and gallbladder cancer. The regimen integrates **QL1706**, a bifunctional MabPair product developed by Qilu Pharmaceutical that contains two engineered monoclonal antibodies: **iparomlimab** (targeting PD-1) and **tuvonralimab** (targeting CTLA-4). This dual checkpoint inhibition is combined with the **GemOX** chemotherapy doublet (**gemcitabine** and **oxaliplatin**) and **lenvatinib**, a multi-kinase inhibitor that targets several receptor tyrosine kinases involved in angiogenesis and tumor proliferation, including VEGFR1-3 and FGFR1-4. The goal of this multi-modal approach is to achieve significant tumor shrinkage to allow for surgical resection in patients whose tumors were previously considered borderline or unresectable. The therapy is currently being studied in a Phase 2 clinical trial sponsored by Tianjin Medical University Cancer Institute and Hospital.

Other names

QL1706 + GemOX + lenvatinibIparomlimab and Tuvonralimab Injection combined with GemOX and lenvatinib